Consequences of antipsychotic medications for the dementia patient

American Journal of Psychiatry

Volumn 168, Issue 8, 2011, Pages 767-769

  Devanand, D P ^a,b   Schultz, Susan K ^a,b  

^a Columbia University ^*  (United States)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CITALOPRAM; NEUROLEPTIC AGENT; OLANZAPINE; PLACEBO; QUETIAPINE; RISPERIDONE;

AGE; AGITATION; ALZHEIMER DISEASE; ANTICHOLINERGIC EFFECT; CLINICAL TRIAL (TOPIC); COGNITIVE DEFECT; COMORBIDITY; DEMENTIA; DISEASE SEVERITY; DRUG DOSE TITRATION; DRUG INDICATION; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EDITORIAL; FOOD AND DRUG ADMINISTRATION; HUMAN; MEDICAL DECISION MAKING; MINI MENTAL STATE EXAMINATION; NEUROPSYCHOLOGICAL TEST; PRIORITY JOURNAL; PSYCHOSIS; RISK BENEFIT ANALYSIS; SEDATION;

AGED; ALZHEIMER DISEASE; ANTIPSYCHOTIC AGENTS; CONFUSION; DISEASE PROGRESSION; DRUG SUBSTITUTION; DRUG TOXICITY; HUMANS; MENTAL STATUS SCHEDULE; NEUROPSYCHOLOGICAL TESTS; PSYCHOMOTOR AGITATION; PSYCHOTIC DISORDERS; RISK FACTORS;

EID: 80052429238     PISSN: 0002953X     EISSN: 15357228     Source Type: Journal    
DOI: 10.1176/appi.ajp.2011.11040629     Document Type: Editorial

References (8)

1. Vigen C.L.P., Mack W.J., Keefe R.S.E., Sano M., Sultzer D.L., Stroup T.S., Dagerman K.S., Hsiao J.K., Lebowitz B.D., Lyketsos C.G., Tariot P.N., Zheng L., Schneider L.S.: Cognitive effects of atypical antipsychotic medications in patients with Alzheimer's disease: Outcomes from CATIE-AD. Am J Psychiatry 2011; 168:831-839
2. Ballard C., Waite J.: The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer disease. Cochrane Database Syst Rev 2006; 1:CD003476
3. Raivio M.M., Laurie J.V., Strandberg T.E., Tilvis R.S., Pitkälä K.H.: Neither atypical nor conventional antipsychotics increase mortality or hospital admissions among elderly patients with dementia: A 2-year prospective study. Am J Geriatr Psychiatry 2007; 15:416-424
4. Simoni-Wastila L., Ryder P.T., Qian J., Zuckerman I.H., Shaffer T., Zhao L.: Association of antipsychotic use with hospital events and mortality among Medicare beneficiaries residing in long-term care facilities. Am J Geriatr Psychiatry 2009; 17:417-427
5. Liperoti R., Onder G., Landi F., Lapane K.L., Mor V., Bernabei R., Gambassi G.: All-cause mortality associated with atypical and conventional antipsychotics among nursing home residents with dementia: A retrospective cohort study. J Clin Psychiatry 2009; 70:1340-1347
6. Chen Y., Briesacher B.A., Field T.S., Tjia J., Lau D.T., Gurwitz J.H.: Unexplained variation across US nursing homes in antipsychotic prescribing rates. Arch Intern Med 2010; 170:89-95
7. Kales H.C., Zivin K., Kim H.M., Valenstein M., Chiang C., Ignacio R., Ganoczy D., Cunningham F., Schneider L.S., Blow F.C.: Trends in antipsychotic use in dementia, 1999-2007. Arch Gen Psychiatry 2011; 68:190-197
8. Valiyeva E., Herrmann N., Rochon P.A., Gill S.S., Anderson G.M.: Effect of regulatory warnings on antipsychotic prescription rates among elderly patients with dementia: A population-based time-series analysis. CMAJ 2008; 179:438-446